Treatment of Acute Pancreatitis With Ketorolac

• Status: Terminated
• Trial end date: 2019-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients with acute pancreatitis will be randomly assigned in either study group to receive oral (injection) Ketorolac or the control group. In patients who cannot tolerate oral medications, ketorolac injection will be used.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ilam University of Medical Sciences
• Treatments: Ketorolac; Ketorolac Tromethamine

Criteria

Inclusion Criteria:

1. Predicted Severe Acute Pancreatitis

2. Enrollment within 72 hours of diagnosis

3. Obtaining informed consent

4. Age >18 years

Exclusion Criteria:

1. Heart disease, Hypertension

2. Hemorrhagic diathesis, Incomplete hemostasis, High risk of bleeding

3. Lactating women

4. Pregnancy

5. Advanced renal disease

6. Hypersensitivity to ketorolac, aspirin, other NSAIDs

7. Concurrent use with aspirin, other NSAIDs, probenecid, or pentoxifylline

8. Active or history of peptic ulcer disease

9. Recent or history of GI bleeding or perforation

10. Inflammatory bowel disease

11. Severe hepatic impairment or active hepatic disease